Dr. Nirmish R. Shah, MD

Dr. Shah practices at Duke University Hospital in Durham, North Carolina, part of Duke University.

Dr. Shah's NPI, 1033113899, was assigned on June 9, 2005. Dr. Shah graduated from American University of the Caribbean School of Medicine in 2000. Dr. Shah holds North Carolina license 200500111.

Dr. Shah's primary practice is Duke University Hospital, at 2301 Erwin Rd, Durham, NC 27705 in Durham County. The practice phone is (919) 684-8111.

Dr. Shah's primary practice is Duke University Hospital in Durham, North Carolina, part of Duke University. Dr. Shah is also affiliated with Duke Regional Hospital. The medical group on file is Duke Health Integrated Practice. Dmand AI also links Dr. Shah to 1 more hospital and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shah practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Shah's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Shah is licensed in North Carolina.

Dmand AI lists breast cancer, colorectal cancer and deep vein thrombosis (DVT) among the conditions Dr. Shah treats.

CMS data shows 18 Medicare services from Dr. Shah across 1 procedure code in 2023, for 23 Medicare patients. Medicare paid $1,651 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 23 Medicare patients who saw Dr. Shah in 2024. 75% of them have high blood pressure, and 61% have high cholesterol. Their average risk score is 3.18, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shah's median patient age at 36, with 44% women.

In 2024, Dr. Shah wrote 102 Medicare Part D claims for 31 patients. 72% of them were for generic drugs. CMS names the drug for 63 of them, across 2 drugs with 11 or more claims each, at $9,031 in total drug cost. In 2023, CMS named 49 claims across 1 drug.

Dr. Shah accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 81 papers to Dr. Shah, published from 2011 to 2025. 2023 was the busiest year, with 10. The most frequent topics are Anemia, Sickle Cell, Pain and Chronic Pain. Dr. Shah has published most often in Blood Adv. Dr. Shah's most frequent co-authors are Victor R. Gordeuk, MD, Sherif Mohamed Badawy, MD and Jeffrey Avins Glassberg, MD.

Dmand AI links Dr. Shah to 16 clinical trials, 4 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Anemia, Sickle Cell, Anemia, Hemolytic, Congenital and Vaso-Occlusive Crises. Duke University sponsors the most, 8. Open Payments lists research payments to Dr. Shah that name 1 trial.

CMS Open Payments shows 916 general payments to Dr. Shah from 21 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 54% of the total. Novartis Pharmaceuticals Corporation paid the most, $317,047. It also lists 81 research payments totaling $161,063 from 2017 to 2025, naming 1 clinical trial.

Dr. Shah graduated from American University of the Caribbean School of Medicine in 2000.

Dr. Shah is in network with 17 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.